in a patient with decompensated alcoholic liver cirrhosis increased urinary volume from 30 ml/h to 500 ml/h, creatinine clearance from 24 to 65 ml/min, and fractional sodium excretion from 086% to 11*1%. Free water clearance decreased from -10.2 ml/h to -26-2 ml/h and noradrenaline plasma concentrations dropped from 2-04 to 1-37 ng/ml. After stopping Ornipressin infusion all values returned to initial concentrations. Possible effects are an increasge of renal blood flow secondary to an increase in arterial blood pressure, possibly potentiated by the vasodilatory effect of the fall in noradrenaline and/or angiotensin concentration.
spironolactone (200 mg twice daily for the last three months). Serum osmolality and concentrations of creatinine, potassium, and sodium are listed in Table 1 .
After a four hour control period 18 units of ornipressin (POR 8R) were infused over the following four hours. There was a marked rise in systolic blood pressure from 92 mmHg to 130 mmHg, systemic vascular resistance rose from 409 dyn sec cm-5 to 701 dyn sec cm-5. Heart rate decreased (Table 2) . Urinary volume increased from 120 ml/four hours to 2000 ml/four hours, creatinine clearance rose from 25 to 68 ml/min, free water clearance from -10*2 to -26-2 ml/hour, and fractional sodium excretion from 0*86% to 11*1% (Table 3) . Noradrenaline concentration decreased from 2-04 ng/ml to 1*37 ng/ml (Table 1) .
After stopping Ornipressin infusion all values returned to near the control levels (Tables 1-3 ). The procedure was repeated on the following day with similar results. Ornipressin was then infused continuously (1.5 U/h) until the patient underwent successful liver transplantation.
Discussion
Although impairment in renal water and sodium excretion is a commonly encountered clinical problem in cirrhotic patients, the mechanisms responsible for this abnormality are uncertain and treatment is still very unsatisfactory. In a single case we found an increase of urinary volume, creatinine clearance and sodium excretion caused by an infusion of Ornipressin in a low dose (4.5 U/hour). A different vasopressin derivate (2-phenylalanine 8-lysine vasopressin) caused a rise in blood pressure and increased renal blood flow only in those patients with cirrhosis. This suggested that the increase in glomerular filtration rate followed the increase in systemic pressure,2 and we feel that this is the most likely explanation in this case. The effect on filtration rate might have been potentiated by renal vasodilatation. Noradrenaline output is known to increase in decompensated cirrhosis,3 and the reduction in this hormone shown in our case could, as suggested for PLV-2,1 cause dilatation of renal A change in aldosterone activity cannot be the cause of the natriuresis, because the patient was on spironolactone throughout the experiment. The rise in urinary sodium concentration was not marked, and most of the increased fractional sodium excretion was almost certainly caused by an increased rate of filtration of plasma.
As this is a report of a single case, these results will need to be confirmed by further cases. 
